Latest News on GRAL

Financial News Based On Company


Advertisement
Advertisement

GRAIL Inc (GRAL) (Q3 2026) Earnings Call Highlights: FDA Nod on the Horizon as Galleri Gains ...

https://sg.finance.yahoo.com/news/grail-inc-gral-q3-2026-010555245.html
GRAIL Inc. held its Q3 2026 earnings call, highlighting a favorable FDA Advisory Committee vote for its Galleri multi-cancer early detection test, with potential FDA approval by early Q1 2027. Despite a modest 4% year-over-year revenue growth in Q3 and a decline in adjusted gross margin, test volumes increased significantly, and the company expanded its sales force and Epic integrations. GRAIL ended the quarter with a strong cash position and outlined strategies for FDA approval, reimbursement, and competitive differentiation, while acknowledging the impact of a pricing promotion and the resumption of the Illumina royalty.

GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth

https://www.tradingview.com/news/zacks:86e352dcd094b:0-grail-q3-earnings-ahead-galleri-test-adoption-to-drive-growth/
GRAIL, Inc. (GRAL) is set to release its Q3 2026 results on November 4, with expectations of increased revenue driven by the adoption of its Galleri test. The company anticipates growth from physician adoption, expanding digital health partnerships, and positive clinical evidence, despite a current Zacks Rank of #4 (Sell). Other medical stocks like TG Therapeutics, Revvity, and Acadia Healthcare are highlighted as potential strong buys.

Behavioral Patterns of GRAL and Institutional Flows

https://news.stocktradersdaily.com/news_release/81/Behavioral_Patterns_of_GRAL_and_Institutional_Flows_102926112802_1793287682.html
This article from Stock Traders Daily analyzes the behavioral patterns and institutional flows for Grail Inc Com (NASDAQ: GRAL), providing key findings and AI-generated trading strategies. It outlines position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis for near-term, mid-term, and long-term outlooks. The analysis suggests strong near-term sentiment but a neutral mid and long-term outlook, with compelling upside potential due to no remaining resistance levels above the current price.

Who Is Paying For GRAIL’s Cash Burn?

https://www.trefis.com/stock/gral/articles/618486/who-is-paying-for-grails-cash-burn/2026-10-13
GRAIL (GRAL) has consistently burned cash, spending $80 million in the June 2026 quarter, burning 182% of its sales. While its cash reserves of $860 million could last about eleven quarters at the current burn rate, shareholders have primarily financed this through increased share count, with debt playing a minor role. The company is anticipating FDA approval for its Galleri test in early 2027, which management expects to significantly improve its financial situation as most insurers and employers are waiting for this approval.

GRAIL's Chief Growth Officer Andrew Partridge Sells 7,873 Shares to Cover Tax Withholding

https://kalkinemedia.com/us/news/announcements/grails-chief-growth-officer-andrew-partridge-sells-7873-shares-to-cover-tax-withholding
Andrew John Partridge, Chief Growth Officer at GRAIL, Inc. (NASDAQ: GRAL), sold 7,873 common shares on October 5, 2026. This automatic "sell-to-cover" transaction was executed to satisfy tax withholding requirements related to award vesting. After the sale, Partridge retains beneficial ownership of 155,865 GRAIL common shares.
Advertisement

To cover vesting taxes, GRAIL (GRAL) CFO Aaron Freidin sells 23,619 shares.

https://www.stocktitan.net/sec-filings/GRAL/form-4-grail-inc-insider-trading-activity-ef63abd42fcc.html
GRAIL, Inc. Chief Financial Officer Aaron Freidin sold 23,619 common shares on October 5, 2026, at a weighted-average price of $146.39 per share. These shares were automatically sold by a broker in a "sell-to-cover" transaction to handle withholding taxes related to award vesting. After this transaction, Freidin directly holds 225,364 shares, and no Rule 10b5-1 plan was reported.

This buzzy biotech stock is up 60% this year. Cramer's advice on building a stake

https://www.cnbc.com/2026/10/06/cramer-grail-stock-galleri-fda-approval.html
Jim Cramer discussed Grail (GRAL) stock, noting its 60% year-to-date gain despite a recent dip. He suggests that while Grail has potential, its current valuation makes it speculative, advising investors to start with a small position and build gradually on weakness. The company's Galleri blood test for cancer screening is awaiting FDA approval, which Cramer believes could be a "gamechanger" for insurance coverage despite current questions regarding its effectiveness and high sales valuation.

An officer sold 7,873 shares to cover vesting taxes at GRAIL (NASDAQ: GRAL).

https://www.stocktitan.net/sec-filings/GRAL/144-grail-inc-sec-filing-ef3b6d54321f.html
GRAIL officer Andrew Partridge reported the sale of 7,873 common shares, valued at approximately $1.15 million, to cover tax withholding obligations from restricted stock unit vesting. The shares were acquired upon vesting on October 3, 2026, and sold on October 5, 2026. ETRADE Financial Corporation handled the transaction on NASDAQ.

Form 144 GRAIL, Inc. Filed by: Freidin Aaron

https://www.streetinsider.com/SEC+Filings/Form+144+GRAIL%2C+Inc.+Filed+by%3A+Freidin+Aaron/27150447.html
Aaron Freidin, an officer of GRAIL, Inc., has filed a Form 144 to sell 23,619 shares of common stock valued at $3,457,599.58 through ETRADE FINANCIAL CORPORATION on October 5, 2026. These shares were acquired on October 3, 2026, upon the vesting of restricted stock units. The filing also reports previous sales by Freidin in August and September 2026 to cover tax withholding obligations.

GRAIL Inc. Officer Andrew Partridge Files Form 144 to Sell 7,873 Shares for RSU Tax Withholding

https://kalkinemedia.com/us/news/announcements/grail-inc-officer-andrew-partridge-files-form-144-to-sell-7873-shares-for-rsu-tax-withholding
Andrew Partridge, an officer at GRAIL, Inc., has filed a Form 144 to sell 7,873 shares of the company's common stock, valued at approximately $1.15 million. This sale is intended to cover tax withholding obligations that arose from the vesting of restricted stock units on October 3, 2026. No prior securities sales by Partridge have been reported in the last three months.
Advertisement

After 45,840 shares vest, a GRAIL (GRAL) officer proposes selling stock to cover taxes.

https://www.stocktitan.net/sec-filings/GRAL/144-grail-inc-sec-filing-ddff6ccffd2f.html
GRAIL officer Aaron Freidin has proposed selling 23,619 common shares valued at approximately $3.46 million, with an anticipated sale date of October 5, 2026. This proposed sale is intended to cover tax withholding obligations that arose from the vesting of 45,840 restricted stock units on October 3, 2026. The filing also notes previous sales by Freidin in August and September 2026.

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026

https://www.prnewswire.com/news-releases/grail-to-present-new-data-from-nhs-galleri-and-pathfinder-2-at-edcc-and-esmo-congress-2026-302898855.html
GRAIL, Inc. is set to present new data from its NHS-Galleri trial and PATHFINDER 2 study at the Early Detection of Cancer Conference (EDCC) and the European Society for Medical Oncology (ESMO) Congress in October 2026. The presentations will highlight the performance of the Galleri multi-cancer early detection (MCED) test, focusing on its clinical performance, health equity, real-world implementation, and its potential to improve cancer screening by detecting cancers earlier. Data will cover the efficiency of diagnostic workups, detection across diverse cancer types and racial/ethnic groups, and the potential impact of annual screenings on reducing emergency diagnoses.

Why GRAIL (GRAL) Is Up 12.9% After Positive FDA Panel Verdict On Galleri Trial Results

https://finance.yahoo.com/healthcare/articles/why-grail-gral-12-9-060723811.html
GRAIL (GRAL) stock rose 12.9% following a positive FDA advisory committee vote on its Galleri multi-cancer early detection blood test, supported by strong results from the PATHFINDER 2 study. The test demonstrated high accuracy in detecting multiple cancers and identifying their origin, with a low false-positive rate. This regulatory progress is expected to reinforce GRAIL's investment narrative, although potential risks include high cash burn and the timing of broad reimbursement.

GRAL Stock Extends Run As Bulls Press Momentum

https://stockstotrade.com/news/grail-inc-gral-news-2026_10_02/
GRAIL Inc. (GRAL) stock has surged by 8.29%, continuing a rapid run from the mid-$70s to the mid-$140s in weeks, driven by strong momentum and aggressive buying despite significant financial losses. While the company exhibits a rich valuation and negative margins, its strong cash position and low debt offer operational runway, making it a purely sentiment-driven trading vehicle. Active traders are focusing on GRAL's price action and technical patterns, highlighting the importance of disciplined risk management given its fundamental weaknesses.

UBS Adjusts GRAIL Price Target to $175 From $105, Maintains Buy Rating

https://www.marketscreener.com/news/ubs-adjusts-grail-price-target-to-175-from-105-maintains-buy-rating-ce785ddad08eff2c
UBS has significantly increased its price target for GRAIL, Inc. (GRAL) to $175 from the previous $105, while reaffirming its "Buy" rating. This adjustment follows recent positive developments, including an FDA panel's vote to support GRAIL's cancer detection test, Galleri, moving it closer to potential FDA approval. The news has already led to a notable increase in GRAIL's stock performance.
Advertisement

Grail’s cancer blood test nears landmark FDA approval, but insurance coverage looms

https://whtc.com/2026/10/02/grails-cancer-blood-test-nears-landmark-fda-approval-but-insurance-coverage-looms/
Grail's Galleri blood test is close to FDA approval, which would be a significant step towards wider adoption. However, securing health insurance coverage from both private insurers and government programs like Medicare is the next major hurdle for the multi-cancer early detection test. Widespread coverage could lead to a multi-billion dollar market, but concerns remain regarding follow-up costs, uncertain benefits, and the need for further research to confirm its impact on reducing cancer deaths.

Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms

https://www.reuters.com/legal/litigation/grails-cancer-blood-test-nears-landmark-fda-approval-insurance-coverage-looms-2026-10-02/
Grail's Galleri blood test for early cancer detection has received a positive recommendation from an FDA advisory panel, moving it closer to full approval. While FDA approval is a significant step, the critical hurdle remaining is securing widespread insurance coverage from private insurers and government health programs like Medicare. Analysts project a potential U.S. market of $60 billion annually by 2030 if the tests gain coverage, but doctors still raise concerns about follow-up costs and whether these tests definitively improve patient outcomes.

GRAIL Slides 4.7% as Post-Rally Profit Taking Appears to Offset Recent Bullish Catalysts

https://www.quiverquant.com/news/GRAIL+Slides+4.7%25+as+Post-Rally+Profit+Taking+Appears+to+Offset+Recent+Bullish+Catalysts
GRAIL (GRAL) shares dropped 4.7% due to potential profit-taking after a late-September rally, despite positive regulatory news for its Galleri test and a raised price target from a Wall Street firm. The decline may also be influenced by recent insider sales and a softer market. Insider trading data shows significant sales by executives, while institutional investors show mixed activity in their holdings.

Securities Class Action Lawsuit Filed Against GRAIL, Inc. (GRAL) – Levi & Korsinsky Represents Shareholders

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/securities-class-action-lawsuit-filed-against-grail-inc.-gral-1193747
Levi & Korsinsky, LLP has filed a securities class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made misleading statements regarding its NHS-Galleri trial, concealing that the trial period was insufficient to demonstrate a reduction in Stage III-IV cancers. Following GRAIL's announcement on February 19, 2026, that the primary endpoint was not met, the company's stock price dramatically declined by approximately 50.55%.

3 Reasons to Buy Grail (GRAL) Hand Over Fist in October

https://finance.yahoo.com/markets/stocks/articles/3-reasons-buy-grail-gral-173500652.html
Grail (GRAL), known for its Galleri blood test for early cancer detection, is presented as a strong buy. Despite a setback in an NHS England trial, an FDA panel has endorsed premarket approval, and the company already generates significant revenue from cash sales. Its current valuation is considered reasonable given its long-term growth potential, especially if FDA approval broadens its market.
Advertisement

The Holy Grail In Cancer? FDA Panel Backs Blood Tests.

https://www.investors.com/news/technology/grail-stock-fda-advisory-committee-meeting-galleri-blood-test/
Trading in Grail (GRAL) stock was halted after a Food and Drug Administration panel issued a mixed vote in favor of the company's Galleri blood screening test for cancer. This marks a significant step towards potential FDA approval for the test, which aims to detect various cancers in asymptomatic individuals. Earlier detection of cancer generally leads to easier and more effective treatment.

FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test

https://www.prnewswire.com/news-releases/fda-advisory-committee-votes-in-favor-of-approval-of-grails-galleri-multi-cancer-early-detection-test-302888303.html
GRAIL, Inc. announced that the FDA's Medical Devices Advisory Committee voted favorably for the approval of its Galleri® multi-cancer early detection test (MCED). The committee supported Galleri's safety unanimously, effectiveness by a vote of six to four, and overall benefit-risk profile by seven to two with one abstention. GRAIL will continue to work with the FDA as it completes its review of the PMA application, which is a significant step towards potentially making the test widely available.

FDA panel endorses first-of-a-kind cancer blood test from Grail

https://thehill.com/policy/healthcare/fda-panel-cancer-blood-test-grail/amp/
A federal health advisory panel has endorsed Grail Inc.'s Galleri blood test for detecting signs of various cancers in healthy individuals, despite acknowledging uncertainties about its effectiveness and the need for further study. The panel voted 7-2 that the benefits outweigh the risks, paving the way for potential widespread adoption if the FDA agrees, though they stressed it should supplement, not replace, existing cancer screenings.

FDA panel endorses first-of-a-kind cancer blood test from Grail

https://www.nbcnews.com/health/cancer/cancer-blood-test-faces-high-stakes-fda-review-rcna599426
A federal advisory panel has endorsed Grail Inc.'s Galleri blood test, designed to detect signs of various cancers in apparently healthy individuals. The panel voted 7-2 that the test offers more potential benefits than risks, despite questions about its efficacy. This marks the first time a federal advisory group has backed such an experimental approach, potentially paving the way for wider adoption if the FDA agrees.

FDA advisory panel recommends a first: multi-cancer blood test

https://www.npr.org/2026/09/23/nx-s1-5978122/fda-blood-cancer-test-galleri
An FDA advisory panel has recommended approval for Grail's Galleri blood test, the first multi-cancer detection blood test, for individuals aged 50 and over. While the test can detect up to 50 forms of cancer, concerns were raised about its effectiveness in early detection and potential for false senses of security. The panel's recommendation includes caveats for marketing materials, emphasizing that the test should supplement, not replace, standard cancer screenings.
Advertisement

GRAIL (GRAL) Stock Looks Overvalued On Its 131% One Year Run

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-stock-looks-overvalued-on-its-131-one-year-run/amp
GRAIL (GRAL) stock has surged 131% over the past year, driven by enthusiasm for its Galleri multi-cancer early detection test and recent funding. However, the article suggests the stock looks overvalued based on its Price-to-Sales (P/S) ratio of 29.3x, which is more than double the biotech sector average. While positive FDA commentary and new financing have boosted sentiment, the current valuation raises a warning flag regarding whether the share price growth is sustainable given its sales base.

Samsung’s $110 mn Grail bet poised to pay off as FDA review lifts cancer test hopes

https://www.kedglobal.com/corporate-investment/newsView/ked202609220012
Samsung Electronics and Samsung C&T are experiencing significant unrealized gains from their $110 million investment in Grail Inc., following a 34% share increase after a preliminary FDA review. This development boosts hopes for approval of Grail's flagship cancer blood test, Galleri, which could accelerate Samsung's expansion into cancer screening and digital healthcare across Asia. The article highlights Samsung's broader strategy of investing in biotechnology and diagnostics through various US-based firms to target new growth engines.

GRAIL, Inc. stock surges 33% to $107.97, but RSI hits 81 ahead of FDA call

https://en.cryptonomist.ch/2026/09/22/grail-inc-stock-surges-33-to-107-97-but-rsi-hits-81-ahead-of-fda-call/
GRAIL, Inc. stock surged 33.68% to $107.97 on September 21, driven by optimism for FDA approval of its Galleri cancer test ahead of the September 23 Advisory Committee meeting. Despite the bullish sentiment and strong technical indicators, the stock is deeply overbought with an RSI above 80 on daily and hourly charts, and trading outside its daily Bollinger Bands, suggesting a high risk of mean-reversion or a pullback. Short-term momentum is already showing signs of cooling off, according to the 15-minute chart.

GRAIL Stock Jumped 34% Yesterday. The FDA Just Told Its Investors Why.

https://www.tikr.com/blog/grail-stock-jumped-34-yesterday-the-fda-just-told-its-investors-why
GRAIL stock surged 34% after FDA staff found no major safety or accuracy issues with its Galleri cancer test, ahead of an advisory committee vote. Despite the jump, the average analyst price target of $79 is significantly below the current $108 share price, indicating the Street has not yet caught up to the market's positive reaction. The FDA's remaining questions primarily concern labeling, not the test's core validity or safety, easing investor concerns about approval.

Up to $5.8M in insider stock may be sold at GRAIL, Inc. (GRAL)

https://www.stocktitan.net/sec-filings/GRAL/144-grail-inc-sec-filing-cf679eaf7a8c.html
GRAIL, Inc. (GRAL) insider Joshua Ofman has filed a Rule 144 notice indicating the potential sale of up to 71,452 shares of common stock through Morgan Stanley Smith Barney, valued at approximately $5.77 million. These shares originate from exercised stock options and Restricted Stock Units. The filing also notes previous 10b5-1 sales by Ofman totaling 5,000 shares for $425,098.00 in August 2026.
Advertisement

(GRAL) as a Liquidity Pulse for Institutional Tactics

https://news.stocktradersdaily.com/news_release/10/GRAL_as_a_Liquidity_Pulse_for_Institutional_Tactics_090526072002_1788607202.html
This article provides an AI-driven analysis of Grail Inc Com (NASDAQ: GRAL), indicating mixed sentiment and choppy conditions. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, complete with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal data highlighting support and resistance levels.

Grail CEO Joshua Ofman sells $425,098 in company stock

https://m.investing.com/news/insider-trading-news/grail-ceo-joshua-ofman-sells-425098-in-company-stock-93CH-4883404?ampMode=1
GRAIL, Inc. CEO Joshua J. Ofman sold 5,000 shares of company stock for $425,098 on August 27, 2026, with shares priced between $85.00 and $85.11. Despite the stock's 142% return over the past year and a recent revenue beat, GRAIL faces volatility and investor concerns due to a loss per share and uncertainty regarding FDA approval. Mr. Ofman now directly holds 397,271 shares after the transaction.

Grail CFO Aaron Freidin sells $671,579 in company stock

https://m.investing.com/news/insider-trading-news/grail-cfo-aaron-freidin-sells-671579-in-company-stock-93CH-4883407?ampMode=1
GRAIL, Inc. CFO Aaron Freidin sold 7,900 shares of company stock for $671,579 on August 27, 2026, after the stock surged 142% but has since pulled back. This sale leaves him with 253,083 directly owned shares. The company recently reported Q2 revenue of $44.7 million, exceeding expectations, but also a significant loss and ongoing challenges with FDA approval, which led to a stock decline.

GRAIL Inc Revenue Breakdown – LSX:A40F8M

https://www.tradingview.com/symbols/LSX-A40F8M/financials-segments/
GRAIL Inc (LSX:A40F8M) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top-performing "Screening" segment, an increase from 104.93 million EUR in the previous year. The United States was the largest geographical contributor, accounting for 116.72 million EUR in revenue.

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

https://www.eagletribune.com/region/class-action-deadline-tonight-faruqi-faruqi-llp-reminds-grail-gral-investors-of-securities-class-action/article_b0b1e8d6-65ef-5c46-bde4-04a7b232a91e.html
Faruqi & Faruqi, LLP is investigating potential securities claims against Grail, Inc. (NASDAQ: GRAL) and reminds investors that the deadline to seek the role of lead plaintiff in a federal securities class action lawsuit is August 4, 2026. The lawsuit alleges that Grail made false and misleading statements regarding the success likelihood of its NHS-Galleri trial, leading to a significant stock price drop after the company announced its primary endpoint was not met. Investors who purchased GRAL stock between May 13, 2024, and February 19, 2026, and suffered losses are encouraged to contact the firm.
Advertisement

Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors

https://www.globenewswire.com/news-release/2026/08/04/3338452/0/en/portnoy-law-firm-announces-class-action-on-behalf-of-grail-inc-investors.html
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Grail, Inc. (NASDAQ: GRAL) who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail made misleading statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial, specifically concerning the sufficiency of the trial period to demonstrate a reduction in Stage III-IV cancers. Investors are encouraged to contact the firm to discuss their legal rights.

GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

https://www.prnewswire.com/news-releases/gral-deadline-today-grail-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302841801.html
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors with substantial losses to join before the August 4, 2026, lead plaintiff deadline. The lawsuit alleges that GRAIL and its executives misled investors about the NHS-Galleri cancer screening trial's design and efficacy, particularly concerning the sufficiency of its three-year follow-up period. GRAIL's stock plummeted by 50.55% on February 19, 2026, after the company disclosed that the trial failed to meet its primary endpoint and admitted to a flawed timeline, leading to over $2.2 billion in market cap loss.

$GRAL Securities: Suffer Losses on Your GRAIL, Inc.

https://www.globenewswire.com/news-release/2026/07/31/3336696/0/en/GRAL-Securities-Suffer-Losses-on-Your-GRAIL-Inc-Investment-BFA-Law-Reminds-Investors-of-the-Securities-Fraud-Lawsuit-to-Recover-Losses.html
Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50% stock drop after the trial failed to meet its primary endpoint. Investors who suffered losses are encouraged to contact BFA Law before the August 4, 2026, lead plaintiff deadline.

GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference

https://www.prnewswire.com/news-releases/grail-to-present-at-the-canaccord-genuity-46th-annual-growth-conference-302839418.html
GRAIL, Inc., a healthcare company focused on early cancer detection, announced it will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11 at 10:00 a.m. ET. The company aims to alleviate the global burden of cancer by using advanced sequencing and machine learning to detect multiple cancer types in earlier stages. A webcast of the presentation will be available on GRAIL's investor relations website.

GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference

https://www.stocktitan.net/news/GRAL/grail-to-present-at-the-canaccord-genuity-46th-annual-growth-v5g4s9wswmxc.html
GRAIL (Nasdaq: GRAL) announced that its management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, at 10:00 a.m. ET. Live and replay webcasts of the presentation will be available through GRAIL's investor relations website, with the replay archived for at least 30 days. This event provides investors with an opportunity to learn more about GRAIL's mission to detect cancer early.
Advertisement

GRAL Deadline: Rosen Law Firm Urges GRAIL, Inc. (NASDAQ: GRAL) Stockholders to Contact the Firm for Information About Their Rights

https://www.businesswire.com/news/home/20260730189315/en/GRAL-Deadline-Rosen-Law-Firm-Urges-GRAIL-Inc.-NASDAQ-GRAL-Stockholders-to-Contact-the-Firm-for-Information-About-Their-Rights
Rosen Law Firm is notifying stockholders of GRAIL, Inc. (NASDAQ: GRAL) about a class action lawsuit for alleged misleading statements made between May 13, 2025, and February 19, 2026. The lawsuit claims GRAIL concealed material adverse facts regarding its NHS-Galleri trial's sufficiency to demonstrate a reduction in Stage III-IV cancers. Shareholders have until August 4, 2026, to file as lead plaintiff.

Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

https://www.globenewswire.com/news-release/2026/07/30/3336260/9788/en/bronstein-gewirtz-grossman-llc-urges-grail-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in Grail’s NHS-Galleri trial, thereby harming investors. Investors who purchased Grail securities between May 13, 2025, and February 19, 2026, are encouraged to join the class action, with a lead plaintiff deadline of August 4, 2026.

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL

https://www.prnewswire.com/news-releases/suewallst-reminds-shareholders-of-a-lead-plaintiff-deadline-of-august-4-2026-in-grail-inc-lawsuit---gral-302838904.html
SueWallSt is reminding shareholders of Grail, Inc. (NASDAQ: GRAL) about the lead plaintiff deadline of August 4, 2026, in a securities class action lawsuit. The lawsuit alleges that Grail's management made misleading representations about the NHS-Galleri trial, leading to a significant stock price drop after the trial's primary endpoint was not met. Investors who purchased GRAL securities between May 13, 2025, and February 19, 2026, and suffered losses, may be eligible for compensation and are encouraged to contact SueWallSt for a no-cost case evaluation.

Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL

https://www.morningstar.com/news/pr-newswire/20260729ny14467/levi-korsinsky-reminds-grail-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-4-2026-gral
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the August 4, 2026 lead plaintiff deadline. The lawsuit alleges that Grail's leadership withheld crucial internal data suggesting the NHS-Galleri trial's three-year design was insufficient to achieve its primary endpoint, leading to a significant stock price drop when the trial failed. Investors who suffered losses are encouraged to contact the firm to recover damages.

GRAIL to Announce Second Quarter 2026 Financial Results

https://www.tradingview.com/news/prnewswire:4e7787a30514b:0
GRAIL, Inc. (Nasdaq: GRAL) announced it will release its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. Interested parties can find a link to the live webcast and recorded replay on the investor relations section of GRAIL's website.
Advertisement

Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors

https://www.globenewswire.com/news-release/2026/07/29/3335669/0/en/bragar-eagel-squire-p-c-reminds-grail-inc-investors-they-have-until-august-4th-to-contact-the-firm-seeking-lead-plaintiff-rol.html
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against GRAIL, Inc. on behalf of investors who purchased common stock between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made false and misleading statements regarding the NHS Galleri trial, specifically concerning its sufficiency to demonstrate a reduction in Stage III-IV cancers and the company's refusal to provide detailed trial results. Investors have until August 4, 2026, to apply for lead plaintiff status.

Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Rol

https://www.globenewswire.com/news-release/2026/07/29/3335669/0/en/Bragar-Eagel-Squire-P-C-Reminds-GRAIL-Inc-Investors-They-Have-Until-August-4th-to-Contact-the-Firm-Seeking-Lead-Plaintiff-Rol.html
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) for allegedly making false and misleading statements regarding its NHS Galleri trial. Investors who purchased GRAIL common stock between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the firm by August 4, 2026, to discuss potentially becoming lead plaintiff. The lawsuit claims GRAIL concealed issues with the trial's ability to demonstrate a reduction in Stage III-IV cancers, leading to a significant stock price drop after negative trial results were revealed on February 19, 2026.

GRAIL webcast on Aug. 5 results open to all interested parties

https://www.stocktitan.net/news/GRAL/grail-to-announce-second-quarter-2026-financial-l0rwltc0vzrt.html
GRAIL (Nasdaq: GRAL) will announce its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. The live webcast and recorded replay will be accessible via the investor relations section of GRAIL's website, and interested participants are encouraged to register in advance.

Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL

https://www.prnewswire.com/news-releases/levi--korsinsky-reminds-grail-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-4-2026---gral-302837434.html
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the pending class action. The lawsuit alleges that Grail's leadership withheld crucial information about the NHS-Galleri trial's insufficient timeline, despite internal data suggesting the trial would fail its primary endpoint. GRAL shares experienced a significant decline of 50.55%, or $51.32 per share, after the trial's failure was disclosed, and investors have until August 4, 2026, to submit lead plaintiff applications.

GRAIL, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 4, 2026

https://www.globenewswire.com/news-release/2026/07/29/3335337/0/en/grail-inc-investors-with-losses-have-until-august-4-2026-to-join-securities-class-action-bernstein-liebhard-llp-announces-deadline.html
Bernstein Liebhard LLP reminds GRAIL, Inc. (NASDAQ: GRAL) investors that they have until August 4, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made materially false and misleading statements between May 13, 2025, and February 19, 2026, leading to artificially inflated stock prices and investor losses. Investors who purchased shares during this period and suffered losses are encouraged to contact the firm.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement